CareRx Stock Forecast for 2023 - 2025 - 2030

Updated on 05/01/2024

Stock Rating
11
Price Target
C$3.50
Consensus
Outperform
Upside
48.31%
Analysts
3
Stock Rating
11
Upside
48.31%
Analysts
3
Price Target
C$3.50

CareRx Stock Forecast and Price Target

If CareRx's stock price reached the average yearlong target of C$3.50 given by three well-known analysts in recent months, there would be a potential upside of approximately 48.31% from its last closing price in April, 2024. This potential increase is based on a high estimate of C$5.25 and a low estimate of C$2.75. If you're considering investing in CRRX stock, it's essential to look at its competitors, too.

C$3.50

48.31% Upside

Buy
Buy

CareRx Fair Value Forecast for 2023 - 2025 - 2030

CareRx's Price has grown in the last four years, jumping from C$0.00 to C$0.00 – an increase of 100.00%. In the next year, analysts predict that Fair Value will reach C$2.51 – an increase of 100.00%. For the next seven years, the forecast is for Fair Value to grow by 100.00%.

2024 Fair Value Forecast
C$2.51
2025 Fair Value Forecast
C$2.74
2026 Fair Value Forecast
C$3.00
2027 Fair Value Forecast
C$3.28
2028 Fair Value Forecast
C$3.59
2029 Fair Value Forecast
C$3.92
2030 Fair Value Forecast
C$4.29

CareRx Revenue Forecast for 2023 - 2025 - 2030

CareRx's Revenue has grown in the last two years, jumping from C$162.20M to C$381.73M – an increase of 135.35%. In the next year, analysts predict that Revenue will reach C$385.10M – an increase of 0.88%. For the next seven years, the forecast is for Revenue to grow by 4.54%.

2024 Rev Forecast
C$0.39B
2025 Rev Forecast
C$0.40B
2026 Rev Forecast
C$0.41B
2027 Rev Forecast
C$0.40B
2028 Rev Forecast
C$0.39B
2029 Rev Forecast
C$0.40B
2030 Rev Forecast
C$0.40B

CareRx Dividend per Share Forecast for 2023 - 2025 - 2030

CareRx Free Cash Flow Forecast for 2023 - 2025 - 2030

2024 FCF Forecast
C$0.02B
2025 FCF Forecast
C$0.03B
2026 FCF Forecast
C$0.02B
2027 FCF Forecast
C$0.02B
2028 FCF Forecast
C$0.02B
2029 FCF Forecast
C$0.02B
2030 FCF Forecast
C$0.02B

CareRx EBITDA Forecast for 2023 - 2025 - 2030

CareRx's EBITDA has increased by 160.36% In the last two years, going from C$8.35M to C$21.74M. In the next year, analysts expect EBITDA to reach C$33.84M – an increase of 55.66%. For the next seven years, the forecast is for EBITDA to grow by 66.93%.

2024 EBITDA Forecast
C$0.03B
2025 EBITDA Forecast
C$0.04B
2026 EBITDA Forecast
C$0.04B
2027 EBITDA Forecast
C$0.03B
2028 EBITDA Forecast
C$0.03B
2029 EBITDA Forecast
C$0.04B
2030 EBITDA Forecast
C$0.04B

CareRx EBIT Forecast for 2023 - 2025 - 2030

In the last two years, CareRx's EBIT has grown, increasing from C$-930.00k to C$7.38M – a growth of 893.55%. In the next year, 0 analysts estimate that CareRx's EBIT will decrease by 63.51%, reaching C$2.69M. According to professional forecasts, in 2030, CareRx's EBIT will decrease by 34.48%, reaching C$4.84M.

2023 EBIT Forecast
C$0.00B
2024 EBIT Forecast
C$0.00B
2025 EBIT Forecast
C$0.00B
2026 EBIT Forecast
C$0.01B
2027 EBIT Forecast
C$0.00B
2028 EBIT Forecast
C$0.00B
2029 EBIT Forecast
C$0.00B
2030 EBIT Forecast
C$0.00B

CareRx EPS Price Prediction Forecast for 2023 - 2025 - 2030

CareRx's EPS has grown in the last four years, jumping from C$-0.95 to C$0.00 – an increase of 100.00%. In the next year, analysts predict that EPS will reach C$-0.05 – an increase of 100.00%. For the next seven years, the forecast is for EPS to grow by 100.00%.

2024 EPS Forecast
C$-0.05
2025 EPS Forecast
C$0.00
2026 EPS Forecast
C$0.37
2027 EPS Forecast
C$0.25
2028 EPS Forecast
C$0.29
2029 EPS Forecast
C$0.23
2030 EPS Forecast
C$0.27